Shareholders Approve 5.9 Million Share Increase for Equity Incentive Plan
ALKS sits 47% above its 52-week low of $25.165.
Summary
Alkermes shareholders approved an increase of 5.9 million shares for the company's equity incentive plan, potentially leading to future dilution, and re-elected all directors.
Key Events · Corporate Governance and Compliance · ALKS
-
Share Pool Expansion Approved
Shareholders approved adding 5.9 million ordinary shares to the 2018 Stock Option and Incentive Plan, increasing the total authorized shares for equity compensation. This approval finalizes a proposal previously disclosed in the definitive proxy statement.
-
Directors Re-elected
All nine nominated directors, including outgoing CEO Richard F. Pops, were re-elected to the Board for a one-year term.
-
Routine Shareholder Approvals
Shareholders also approved executive compensation in an advisory vote, ratified the appointment of PricewaterhouseCoopers LLP as independent auditor, and renewed Board authority for share allotment and disapplication of pre-emption rights under Irish law.
Analysis · ALKS · Life Sciences
Shareholders approved an increase of 5.9 million ordinary shares for the company's 2018 Stock Option and Incentive Plan. This authorization expands the pool of shares available for future equity compensation, which could lead to dilution for existing shareholders if fully utilized. The approval finalizes a proposal previously outlined in the definitive proxy statement.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALKS was trading at $37.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $25.17 to $39.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.